RA Capital Management Updates 9.9% Stake, Discloses Board Appointments

summarizeSummary

RA Capital Management updated its 9.9% beneficial ownership in SAB Biotherapeutics, reflecting company dilution, and disclosed its role in appointing two new directors to the board.

check_boxKey Events

• Beneficial Ownership Update

  RA Capital Management, L.P. and its affiliates reported beneficial ownership of 5,166,424 shares, representing 9.9% of SAB Biotherapeutics' common stock. This update reflects an increase in the issuer's outstanding shares, not new transactions by RA Capital, and follows the company's recent $175 million financing.

• Board Director Appointments

  The filing disclosed that RA Capital Management recommended David Zaccardelli, Pharm.D, and Rita Jain, M.D., who were appointed to the company's Board of Directors on January 5, 2026, indicating RA Capital's active role in governance.

auto_awesomeAnalysis

This Schedule 13D/A from RA Capital Management updates its beneficial ownership in SAB Biotherapeutics to 9.9% of outstanding common stock. The change in percentage is primarily due to an increase in the company's total outstanding shares, likely from the recent $175 million financing reported in the March 9, 2026 10-K, rather than new acquisitions or dispositions by RA Capital. The filing also reveals that RA Capital recommended two directors, David Zaccardelli and Rita Jain, who were appointed to the Board on January 5, 2026, highlighting RA Capital's active influence in the company's governance.